期刊文献+

盐酸多柔比星脂质体在乳腺癌化学治疗中不良反应观察 被引量:5

下载PDF
导出
摘要 目的:观察盐酸多柔比星脂质体在乳腺癌化学治疗中的不良反应,为临床应用提供参考。方法:手术后乳腺癌患者115例,采用盐酸多柔比星脂质体联合环磷酰胺进行4个周期化疗,观察药物不良反应。结果:4个周期化疗后,患者骨髓抑制表现为白细胞、中性粒细胞、血红蛋白和血小板减少,均为Ⅰ~Ⅱ级不良反应,白细胞、中性粒细胞减少平均发生率分别为25.9%和16.3%,血红蛋白及血小板减少平均发生率为4.3%及2.1%。肝、肾功能异常及心脏毒性反应平均发生率分别为3.9%,0.9%和1.1%,主要发生于第1周期化疗后。脱发、恶心呕吐平均发生率分别为16.3%和35.0%,手足综合征发生率较高为48.5%,随着化疗进程发生率逐渐降低。结论:在以盐酸多柔比星脂质体为基础的化疗过程中,除了重点关注骨髓抑制外,也要积极处理手足综合征。
出处 《交通医学》 2022年第1期74-76,80,共4页 Medical Journal of Communications
  • 相关文献

参考文献6

二级参考文献60

  • 1ALLEN T M, HANSEN C B, DE MENEZES D E L. Pharmacokinetics of long-circulating liposomes [J]. Adv Drug Deliv Rev, 1995, 16(2/3): 267- 284.
  • 2LU W L, QI XR, ZHANG Q, et al. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug [J]. J Pharmacol Sci, 2004, 95(3): 381-389.
  • 3VISANI G, GUIDUCCI B, D'ADAMO F, et al. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma [J]. Leuk Lymphoma, 2005, 46(3): 477-479.
  • 4OFFIDANI M, CORVATTA L, PIERSANTELLI M N, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for newly diagnosed multiple myeloma patients over 65 years [J]. Blood, 2006, 108(7): 2159-2164.
  • 5KAVANAGH J J, LEVENBACK C F, RAMIREZ P T, et al. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer [J]. J Hematol Oncol, 2010(3): 9.
  • 6KESTERSON J P, ODUNSI K, LELE S, et al. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies [J]. Chemother, 2010, 56(2): 108-111.
  • 7GABIZON A A. Slective tumor localization and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes [J]. Cancer Res, 1992, 52(4): 891-896.
  • 8FUJISAKA Y, HORIIKE A, SHIMIZU T, et al. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors Japanese [J]. J Clin Oncol, 2006, 36(12): 768-774.
  • 9O'BRIEN M E, WIGLER N, INBAR M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin FIC1 (CAELYX/Doxif) versus conventional doxorubicin for first-line treatment of metastatic breast cancer [J]. Ann Oncol, 2004, 15(3): 440-449.
  • 10COLEMAN R E, BIGANZOLI L, CANNEY P, et al. A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC- 10993) [J]. Eur J Cancer, 2006, 42(7): 882-887.

共引文献118

同被引文献45

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部